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Abstract
Background: The treatment options for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-
Acinetobacter baumannii (MDR Acb) complex are limited, and the optimal treatment has not been established.
Methods: To compare the efficacy of tigecycline-based with sulbactam (or ampicillin/sulbactam)-based therapy
for pneumonia involving MDR Acb complex, we conducted a retrospective study comparing 84 tigecycline-treated
adult patients during the period August 2007 to March 2010 with 84 sulbactam or ampicillin/sulbactam-treated adult
patients during the period September 2004 to July 2007. Both groups had the matched Acute Physiology and Chronic
Health Evaluation (APACHE) II score and received treatment for at least 7 days.
Results: The mean APACHE II score was 20.1 for both groups. More patients in sulbactam group had ventilator
use (89.3 % versus 69.0 %), bilateral pneumonia (79.8 % versus 60.7 %) and combination therapy (84.5 % versus
53.6 %), particularly with carbapenems (71.4 % versus 6.0 %), while more patients in tigecycline group had delayed
treatment (41.7 % versus 26.2 %) (P <0.05). At the end of treatment, more patients in sulbactam group had airway MDR
Acb complex eradication (63.5 % versus 33.3 %, P <0.05). The clinical resolution rate was 66.7 % for both groups.
The mortality rate during treatment was 17.9 % in sulbactam group, and 25.0 % in tigecycline group (P = 0.259).
The multivariate analysis showed that bilateral pneumonia was the only independent predictor for mortality
during treatment (adjusted odds ratio, 2.717; 95 % confidence interval, 1.015 to 7.272).
Conclusions: Patients treated with either tigecycline-based or sulbactam-based therapy had a similar clinical
outcome, but tigecycline group had a lower microbiological eradiation rate.
Background
Pneumonia involving multidrug-resistant (MDR) Acineto-
bacter calcoaceticus-Acinetobacter baumannii (Acb) com-
plex usually occurs in critically ill patients and is associated
with unfavorable outcomes [1–3]. For MDR Acb complex
resistant to most currently available antibiotics, including
β-lactams, fluoroquinolones, and aminoglycosides, there
are only a few treatment options, such as tigecycline,
sulbactam, and colistin [4, 5].
Tigecycline is a glycylcycline with in vitro activity
against MDR Acb complex [6]. The comparison ana-
lysis from the U.S. Food and Drug Administration
showed that tigecycline treatment had a higher mor-
tality rate than other antimicrobials in ventilator asso-
ciated pneumonia (VAP) [7]. A recent study also
reported a significantly lower cure rate in clinically
evaluable patients with VAP treated with tigecycline
when compared to imipenem (47.9 % versus 70.1 %)
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[8]. However, for pneumonia caused by MDR Acb
complex resistant to carbapenems and other classes of
antibiotics, off label use of tigecycline was common in
clinical practice, and the clinical response rates ranged
from 60 to 88 % in prior studies [9–11]. Sulbactam is
a β-lactamase inhibitor with antimicrobial activity
against Acinetobacter species [12]. It is available alone
or in combination with ampicillin, and ampicillin
doesn’t contribute activity or synergism against A.
baumannii [12]. Sulbactam or ampicillin/sulbactam
had clinical response rates ranging from 67 to 75 % for
pneumonia involving MDR A. baumannii (MDRAB) or
MDR Acb complex in prior studies [13–15].
In our hospital, tigecycline was not available until
August 2007. Before that, sulbactam or ampicillin/sul-
bactam might be the only treatment option with in
vitro activity against MDR Acb complex. Thus, we
conducted a retrospective study to compare the effi-
cacy of tigecycline-based with sulbactam (or ampicillin/
sulbactam)-based treatment for pneumonia involving
MDR Acb complex. With a match in the Acute Physi-
ology and Chronic Health Evaluation (APACHE) II
score for both groups, a comparison was made be-
tween tigecycline-treated adult patients during the
period August 2007 to March 2010 and sulbactam (or
ampicillin/sulbactam)-treated adult patients during the
period September 2004 to July 2007. The clinical effi-




Chang Gung Memorial Hospital (CGMH)-Linkou is a
university-affiliated medical center providing both pri-
mary and tertiary health care in northern Taiwan. This
retrospective study has been approved by institutional
review boards of CGMH- Linkou (Number: 99-1478B
and 100-0294B). The ethics committee granted a waiver
for informed consent to be obtained.
Study design, patients and treatments
All hospitalized patients who were ≧ 18 years old and
had pneumonia involving MDR Acb complex treated
with tigecycline between August 2007 and March
2010, and sulbactam or ampicillin/sulbactam between
September 2004 and July 2007, were reviewed. Each
tigecycline-treated patient was matched to one sulbac-
tam or ampicillin/sulbactam-treated patient based on
identical values of APACHE II score and chart number
sequence. Patients were excluded if they did not have a
matched control or had a combination therapy with tige-
cycline and sulbactam (or ampicillin/sulbactam). Patients
with initial bacteremia were also excluded since tigecycline
treatment for bacteremia was controversial.
Pneumonia was diagnosed if the patient had a radio-
graphic infiltrate that was new or progressive, along with
at least two of the following clinical characteristics: new
onset of fever (≧ 38 °C) or hypothermia (< 35.5 °C),
leucocytosis (leucocyte count > 12000 cells/mm3) or
leucopenia (leucocyte count < 4000 cells/mm3), decline
in oxygenation (O2 saturation < 90 %), and increasing
amount of purulent sputum [16]. Pneumonia involving
MDR Acb complex was defined as clinical evidence of
pneumonia with sputum or tracheal aspirate cultures
positive for MDR Acb complex from 1 week before to
3 days after the first dose of tigecycline or sulbactam or
ampicillin/sulbactam. Tracheal aspirate and sputum
specimens were sent for bacterial culture only if their
Gram’s stains showed at least 25 neutrophils and less
than 10 epithelial cells per low-power field. Growth was
assessed semi-quantitatively. The etiologic pathogen of
pneumonia was determined if the tracheal aspirate or
sputum culture had an at least moderate growth, i.e., the
growth confined up to primary streaking line and > 5
colonies in secondary streaking zone [17]. Polymicrobial
pneumonia was defined as one or more additional etio-
logic bacterial species concurrently isolated from the re-
spiratory tract during treatment.
All patients in tigecycline group received tigecycline
for at least 7 days, with a 100-mg loading dose followed
by 50 mg administered intravenously every 12 h. All pa-
tients in sulbactam group received intravenous sulbac-
tam 1 g or ampicillin/sulbactam 3 g (at a ratio 2:1)
every 6 or 8 h for at least 7 days. Dose and dosing inter-
val were adjusted according to serum creatinine levels.
Combination therapy was defined as simultaneous use
of another class of antibiotics for at least 3 days. These
antibiotics included carbapenems (meropenem or imi-
penem), fluoroquinolones (ciprofloxacin or levofloxacin),
amikacin, cephalosporins (ceftazidime or cefepime), piper-
acillin, piperacillin-tazobactam, colistimethate, and aztreo-
nam. Delayed treatment was defined as more than 3 days
between the detection of airway MDR Acb complex iso-
lates and the first dose of tigecycline or sulbactam or
ampicillin/sulbactam.
Microbiology
Identification of Acb complex depended upon Gram
staining and conventional biochemical tests [18]. Briefly,
the isolates were identified as species of the genus Acine-
tobacter based on the following properties: aerobic,
Gram-negative, nonmotile coccobacillary rods with a
nonfermentative, catalase-positive and oxidase-negative
reaction. Acinetobacter species with glucose-oxidizing
non-haemolytic characteristics were classified as Acb
complex. Antimicrobial susceptibility was determined
and interpreted according to the criteria of Clinical and
Laboratory Standards Institute by disk diffusion method
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[19]. Susceptibility to tigecycline was determined using disk
diffusion method with Mueller-Hinton agar (BD Microbiol-
ogy Systems, Cockeysville, MD) with the resistant break-
point at ≧ 16 mm and susceptible breakpoint at ≦ 12 mm
[20]. An isolate with full or intermediate resistance to ami-
kacin, gentamicin, cefepime, ceftazidime, aztreonam, piper-
acillin, piperacillin-tazobactam, ciprofloxacin, imipenem
and meropenem was defined as MDR Acb complex [21].
Cultures were collected from 1 week before the first
dose of tigecycline or sulbactam (or ampicillin/sulbac-
tam) to the discharge of patients. Pathogens, sites of
growth and susceptibility testing were recorded. Micro-
bial eradication of MDR Acb complex was defined as no
growth of Acb complex or susceptibility change from
MDR strains to susceptible strains in Acb complex in
follow-up respiratory tract cultures before and 7 days
after treatment cessation. Relapse was defined as new
isolation of MDR Acb complex from the respiratory
tract cultures within 2 weeks after initial eradication. Ini-
tial bacteremia was defined as bacteremia at the begin-
ning of treatment, which meant at least one positive
blood culture 1 week before to 3 days after the first dose
of tigecycline or sulbactam or ampicillin/sulbactam.
Bacteremia during treatment was defined as at least one
positive blood culture 3 days after to the end of treatment.
Demography and comorbidity
Data on age, sex, surgery, and co-morbid illness were
gathered by reviewing in-patient medical records. Co-
morbid illness included hepatic dysfunction of a serum
total bilirubin level over 2.5 mg/dL or liver cirrhosis,
renal insufficiency of a serum creatinine level above
2.0 mg/dL or requirement of dialysis, chronic pulmonary
disease, heart disease, diabetes mellitus, immune com-
promise, and hematological or solid organ malignancy.
Immune compromise was defined by at least one of the
following: use of prednisone or equivalent over 20 mg per
day for at least 2 weeks, organ transplant recipient, human
immunodeficiency virus infection or acquired immuno-
deficiency syndrome, neutropenia (absolute neutrophil
count less than 500 cells/mm3), use of immunosuppres-
sive agents, and concurrent hematological malignancy.
Clinical conditions and outcomes
Ventilator use, vital signs, and infections other than
pneumonia during treatment were recorded. Deferves-
cence was defined as normal body temperature for at
least 3 days at the end of treatment. Severity of illness
was assessed by a modified APACHE II score, which was
recorded within 48 h before or after the first dose of
tigecycline or sulbactam or ampicillin/sulbactam. The
30-day mortality was defined as death occurring within
30 days after treatment. The chest radiographs were
evaluated by at least two investigators. A series of chest
radiographs were evaluated during treatment. Clinical
resolution of pneumonia at the end of treatment was
defined as (1) decreased pulmonary infiltrate, and (2)
survival with stationary findings on chest radiographs
and defervescence. Thus, patients with persistent fever
or death during treatment would be defined as clinical
failure if infiltrates were stationary. Progressing infil-
trates were defined as clinical failure.
Statistical methods
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences for Windows
(Version 15.0; SPSS Inc., Chicago, IL, USA). Categor-
ical variables were compared using χ2 test or Fisher
exact test, as appropriate. Continuous variables were
tested for normality of distributions by Kolmogorov–
Smirnov test, and then compared by Student’s t-test or
the Mann-Whitney U test, as appropriate. Odds ratios
(ORs) and 95 % confidence interval (CI) were calcu-
lated. The survival curve was plotted by means of the
Kaplan-Meier method, and the log rank test was used
to compare univariate survival distribution between
tigecycline and sulbactam groups. Variables with a P
value < 0.1 in univariate analysis and tigecycline use
were included in a logistic regression model for multi-
variate analysis. All tests were two-tailed, and a P value
of < 0.05 was considered significant.
Results
Patients, demography and concomitant diseases
One hundred and sixteen tigecycline-treated episodes of
pneumonia involving MDR Acb complex were identi-
fied in 112 patients, while 177 sulbactam or ampicllin/
sulbactam-treated episodes were identified in 173 pa-
tients. Finally, 84 tigecycline-treated patients were en-
rolled and matched to 84 patients treated with sulbactam
(26 patients) or ampicillin/sulbactam (58 patients). The
mean APACHE II score was 20.1 for both groups. In tige-
cycline group, 59 (70.2 %) and 25 (29.8 %) patients had
positive MDR Acb complex cultures from tracheal aspi-
rates and sputum, respectively. In sulbactam group, 73
(86.9 %) and 11 (13.1 %) patients had that from tracheal
aspirates and sputum, respectively. There was no signifi-
cant difference in age, gender, and concomitant diseases
between the two groups (Table 1).
Clinical conditions
Patients in sulbactam group had more ventilator use
(89.3 % versus 69.0 %) and bilateral pneumonia (79.8 %
versus 60.7 %) than those in tigecycline group. There
were no significant differences between these two groups
in the overall rates of polymicrobial pneumonia and
multisite infections. Pseudomonas aeruginosa and Methi-
cillin-resistant Staphylococcus aureus were the most
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Table 1 The comparison analysis of demography, concomitant diseases, clinical features, and outcomes between tigecycline (TG)
and sulbactam (SB) groups
Variables TG groupa SB groupa p OR (95 % CI)
n = 84 n = 84
Demographic parameters
Age, yr 69.6 (15.9) 70.6 (15.6) 0.689
Male gender 57 (67.9) 58 (69.0) 0.868 0.946 (0.494–1.814)
Concomitant diseases
Hepatic dysfunction 12 (14.3) 6 (7.1) 0.134 2.167 (0.773–6.075)
Renal insufficiency 32 (38.1) 32 (38.1) 1.000 1.000 (0.536–1.864)
Chronic pulmonary disease 22 (26.2) 20 (23.8) 0.722 1.135 (0.564–2.284)
Heart disease 13 (15.5) 7 (8.3) 0.153 2.014 (0.761–5.333)
Diabetes mellitus 26 (31.0) 35 (41.7) 0.149 0.628 (0.333–1.183)
Immune compromise 13 (15.5) 11 (13.1) 0.659 1.215 (0.511–2.891)
Malignancy 15 (17.9) 20 (23.8) 0.342 0.696 (0.328–1.474)
Surgery 22 (26.2) 15 (17.9) 0.193 1.632 (0.778–3.423)
Clinical conditions
APACHE II Score 20.1 (6.1) 20.1 (6.1) 1.000
Ventilator use 58 (69.0) 75 (89.3) 0.001 0.268 (0.117–0.615)
Pneumonia involving bilateral lung 51 (60.7) 67 (79.8) 0.007 0.392 (0.197–0.781)
Polymicrobial pneumonia, overall 66 (78.6) 62 (73.8) 0.469 1.301 (0.638–2.654)
Polymicrobial pneumonia, coinfection with
MRSA 26 (31.0) 34 (40.5) 0.198 0.659 (0.349–1.245)
Pseudomonas aeruginosa 33 (39.3) 23 (27.4) 0.102 1.716 (0.896–3.285)
Klebsiella spp.b 12 (14.3) 5 (6.0) 0.073 2.633 (0.884–7.840)
Escherichia coli 2 (2.4) 2 (2.4) 1.000 1.000 (0.138–7.270)
Enterobacter spp.c 2 (2.4) 2 (2.4) 1.000 1.000 (0.138–7.270)
Serratia marcescens 10 (11.9) 1 (1.2) 0.005 11.216 (1.402–89.724)
Stenotrophomonas maltophilia 6 (7.1) 15 (17.9) 0.036 0.354 (0.130–0.962)
Multisite infections, overall 33 (39.3) 35 (41.7) 0.753 0.906 (0.489–1.678)
With urinary tract infection 13 (15.5) 19 (22.6) 0.238 0.626 (0.287–1.369)
With catheter related infection 2 (2.4) 10 (11.9) 0.017 0.180 (0.038–0.851)
With soft tissue and wound infection 10 (11.9) 5 (6.0) 0.176 2.135 (0.697–6.540)
With intra-abdominal infection 8 (9.5) 4 (4.8) 0.231 2.105 (0.609–7.279)
With invasive fungal infectiond 12 (14.3) 4 (4.8) 0.035 3.333 (1.029–10.799)
Bacteremia during treatment 4 (4.8) 0 (0.0) 0.121 9.447 (0.501–178.291)
With TG or SB-resistant MDR Acb complexe 16 (19.0) 43 (51.2) < 0.0001 0.224 (0.112–0.448)
Treatment
Duration, days 14.6 (5.4) 16.4 (7.6) 0.150
Combination therapy, overall 45 (53.6) 71 (84.5) < 0.0001 0.211 (0.102–0.439)
With cephalosporins 20 (23.8) 8 (9.5) 0.013 2.969 (1.226–7.192)
With colistin 12 (14.3) 0 (0.0) < 0.0001 29.138 (1.695–500.773)
With carbapenems 5 (6.0) 60 (71.4) < 0.0001 0.025 (0.009–0.070)
With aminoglycosides 7 (8.3) 1 (1.2) 0.064 7.545 (0.907–62.744)
With fluoroquinolones 12 (14.3) 4 (4.8) 0.035 3.333 (1.029–10.799)
Delayed treatment 35 (41.7) 22 (26.2) 0.034 2.013 (1.049–3.863)
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common concurrent pathogens for pneumonia, and
urinary tract infection was the most common concurrent
infection. However, more patients had Serratia mar-
cescnes coinfection and invasive fungal infection in tige-
cycline group, and more patients had Stenotrophomonas
maltophilia coinfection and catheter related infection in
sulbactam group. Among the 168 enrolled patients,
bacteremia during treatment was observed in four pa-
tients, and all of them were from tigecycline group (P =
0.121). During treatment, tigecycline-resistant MDR Acb
complex was isolated in 16 (19.0 %) tigecycline-treated
patients, and sulbactam-resistant MDR Acb complex
was isolated in 43 (51.2 %) sulbactam or ampicllin/sulbac-
tam-treated patients (19.0 % versus 51.2 %, P < 0.0001)
(Table 1). In tigecycline group, 71 patients (84.5 %) had
airway MDR Acb complex isolates with full or intermedi-
ate resistance to sulbactam. Tigecycline susceptibility test-
ing was not performed in sulbactam group.
Treatment
The mean treatment duration was 14.6 and 16.4 days for
tigecycline and sulbactam group, respectively. Compared
to the tigecycline group, more patients in sulbactam
group had combination therapy (84.5 % versus 53.6 %),
particularly with carbapenems (71.4 % versus 6.0 %). In
sulbactam group, the most common co-administered
agent were carbapenems (60/71, 84.5 %), followed by
cephalosporins (8/71, 11.3 %), and 32 patients (38.1 %)
had glycopeptides use. In tigecycline group, the most
common co-administered agent was cephalosporins (20/
45, 44.4 %), followed by colistin (12/45, 26.7 %) and
fluoroquinolones (12/45, 26.7 %). Colistin was not avail-
able until May 2007 in our hospital, and co-use of
colistin was only noted in tigecycline group. More pa-
tients in tigecycline group had delayed treatment (41.7 %
versus 26.2 %) (Table 1).
Outcomes
Sulbactam group had a higher rate of airway MDR Acb
complex eradication (63.5 % versus 33.3 %) and defer-
vescence (90.5 % versus 64.3 %) than tigecycline group
at the end of treatment. There was no significant differ-
ence between these two groups in the rates of clinical
resolution, 30-day mortality and mortality during treat-
ment (66.7 % versus 66.7 %; 33.3 % versus 29.8 %; 25.0 %
versus 17.9 %, respectively) (Table 1). The cumulative
survival rate at 30 days was similar between the two
groups by Kaplan-Meier method (Fig. 1).
The predictor for mortality during treatment
In the univariate analysis, the survivors were more likely
to have tigecycline or sulbactam-resistant MDR Acb
complex than the deceased (39.4 % versus 19.4 %)
(Table 2). And most of the resistant isolates in survivors
were from sulbactam group (39/52, 75 %). In the multi-
variate analysis including tigecycline-based treatment
and variables with a P value < 0.1 in the univariate ana-
lysis, bilateral pneumonia was the only independent pre-
dictor for mortality during treatment (adjusted OR,
2.717; 95 % CI, 1.015 to 7.272) (Table 2). Other models
of multivariate analysis including polymicrobial pneumo-
nia, combination therapy, and combination with carba-
penem or colistin also showed that bilateral pneumonia
was the only independent predictor (Table 3).
Table 1 The comparison analysis of demography, concomitant diseases, clinical features, and outcomes between tigecycline (TG)
and sulbactam (SB) groups (Continued)
Outcomes
Airway eradication of MDR Acb complex without relapsef 26 (33.3) 47 (63.5) < 0.0001 0.287 (0.147–0.560)
Defervescence 54 (64.3) 76 (90.5) < 0.0001 0.189 (0.081–0.445)
Image study of lung
Improvement 37 (44.0) 39 (46.4) 0.757 0.908 (0.495–1.668)
Stationary 32 (38.1) 22 (26.2) 0.099 1.734 (0.900–3.342)
Deterioration 15 (17.9) 23 (27.4) 0.140 0.577 (0.276–1.204)
Clinical resolution of pneumonia 56 (66.7) 56 (66.7) 1.000 1.000 (0.526–1.899)
Mortality during treatment 21 (25.0) 15 (17.9) 0.259 1.533 (0.728–3.231)
30-day mortality 28 (33.3) 25 (29.8) 0.618 1.180 (0.615–2.264)
Abbreviations: TG tigecycline, SB sulbactam, OR odd ratio, CI confidence interval, APACHE acute physiology and chronic health evaluation, MRSA methicillin
resistant Staphylococcus aureus, MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii, ESBL extended-spectrum beta-lactamase
aCategorical data are no. (%) of subject, continuous data are expressed as mean (standard deviation)
b16 patients had coinfection with Klebsiella pneumoniae, including 10 with ESBL strains, and 1 had Klebsiella oxytoca-ESBL
c3 patients had coinfection with Enterobacter cloacae, and 1 had Enterobacter aerogenes
d15 patients had candidemia, and 1 had possible invasive aspergillosis diagnosed with positive serum galactomannan
eWith TG-resistant MDR Acb complex during TG treatment in TG group, or with SB-resistant MDR Acb commplex during SB treatment in SB group
f78 patients in TG group and 74 in SB group had available data for evaluation
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Monotherapy of tigecycline and sulbactam
Thirty-nine (46.4 %) patients had tigecycline monother-
apy and 13 (15.5 %) had sulbactam or ampicillin/sulbac-
tam monotherapy. Tigecycline group had significant
lower rates of ventilator use, bilateral pneumonia, and
airway eradication of MDR Acb complex. Both groups
had similar clinical resolution rates. However, tigecycline
group had lower rates of 30-day mortality and mortality
during treatment (25.6 % versus 53.8 %, 17.9 % versus
30.8 %, P >0.05). In the univariate analysis for the pa-
tients with monotherapy, both the survivors and the de-
ceased during treatment had no significant difference in
demography, concomitant diseases, clinical conditions,
and treatment (Table 4).
Discussion
Prior case series studies reported clinical response rates
ranging from 60 to 88 % in tigecycline treatment [9–11],
and 67 to 75 % in sulbactam or ampicillin/sulbactam
treatment for pneumonia involving MDRAB or MDR
Acb complex [13–15]. There were only a few compara-
tive studies investigating the efficacy of tigecycline or
sulbactam, and usually they were compared with colistin
or polymyxin, the other major treatment option for
MDR Acb complex. Betrosian AP et al. reported that
high-dose ampicillin/sulbactam monotherapy and colis-
tin were comparably safe and effective treatment for crit-
ically ill patients with MDRAB VAP. The clinical success
and improvement rate was 76.9 % for ampcillin/sulbac-
tam group and 73.3 % for colistin group [22]. Oliveira
MS et al. reported another study comparing ampicillin/
sulbactam with polymyxins in treating infections caused
by carbapenem-resistant Acinetobacter spp. [23]. In the
study, about half of the enrolled patients had Acineto-
bacter bacteremia, and quarter of them had pneumonia.
The mortality rate during treatment was 33 % in ampi-
cillin/sulbactam group and 50 % in polymyxin group,
and polymyxin use was an independent factor associated
with mortality during treatment [23]. Chuang YC et al.
reported a study comparing tigecycline-based to colistin-
based therapy for MDRAB pneumonia in intensive care
units. The tigecycline group has an excess mortality of
16.7 % (60.7 % versus 44 %, P = 0.04). The excess mortal-
ity of tigecycline is significant only among those with
minimal inhibitory concentration (MIC) > 2 μg/mL, but
not for those with MIC ≦ 2 μg/mL [24].
To our knowledge, the study was the first comparative
study of tigecycline-based versus sulbactam or ampicil-
lin/sulbactam-based treatment for pneumonia involving
MDR Acb complex. Our two patient groups were from
different but successive time periods, and the major
treatment for MDR Acb complex was different in each
time period in our hospital. Before August 2007, sulbac-
tam or ampicillin/sulbactam was the only option prob-
ably with in vitro activity against MDR Acb complex in
our hospital. After that, tigecycline became the major
treatment option because of its high susceptibility rate
to MDR Acb complex. However, the clinical and micro-
biological diagnostic criteria and definition, and stan-
dards of care and infection control were similar in both
time periods. Covariate adjustment with multivariate
analyses and matching with disease severity were per-
formed to reduce bias of the historically controlled
comparison.
The patients from both groups were aged with compli-
cated underlying diseases and high disease severity.
Higher rates of ventilator use and bilateral pneumonia
reflected that sulbactam group might have a higher se-
verity of pneumonia than tigecycline group. A higher
rate of delay use in tigecycline group might reflect the
early policy of tigecycline use in our hospital: usually
tigecycline was not used as empiric or first-line regimen
for nosocomial infection. Both groups had similar clin-
ical outcomes. Bilateral pneumonia was the only inde-
pendent predictor for mortality during treatment in
different models of multivariate analysis. Combination
therapy did not stand out as an independent predictor,
which might be due to difference of combination strat-
egies and regimens between the two patient groups.
Most patients in sulbactam group had combination
with carbapenem for synergistic effect against MDR
Acb complex; however, tigecycline group mainly had
anti-pseudomonal cephalosporins and fluoquinolones
to cover Pseudomonas aeruginosa.
Fig. 1 Comparative survival curves for tigecycline (black line) and
sulbactam (gray line) groups; Log-rank test: p = 0.605. Abbreviations:
SB sulbactam, TG tigecycline
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Table 2 Univariate and multivariate analyses of the predictors for mortality during treatment of tigecycline or sulbactam or ampicillin/
sulbactam for pneumonia involving multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (MDR Acb) complex
Variables Deceaseda Survivorsa Univariate Multivariateb
n = 36 n = 132 p p Adjusted OR (95 % CI)
Demographic parameters
Age, yr 69.8 (14.7) 70.2 (16.0) 0.658
Male gender 26 (72.2) 89 (67.4) 0.583
Concomitant diseases
Hepatic dysfunction 6 (16.7) 12 (9.1) 0.224
Renal insufficiency 15 (41.7) 49 (37.1) 0.619
Chronic pulmonary disease 6 (16.7) 36 (27.3) 0.193
Heart disease 6 (16.7) 14 (10.6) 0.383
Diabetes mellitus 14 (38.9) 47 (35.6) 0.717
Immune compromise 5 (13.9) 19 (14.4) 0.939
Malignancy 11 (30.6) 24 (18.2) 0.105
Surgery 11 (30.6) 26 (19.7) 0.163
Clinical conditions
APACHE II Score 20.3 (7.3) 20.1 (5.8) 0.858
Ventilator use 26 (72.2) 107 (81.1) 0.247
Bilateral pneumonia 30 (83.3) 88 (66.7) 0.053 0.047 2.717 (1.015–7.272)
Polymicrobial pneumonia 29 (80.6) 99 (75.0) 0.488
With MRSA 10 (27.8) 50 (37.9) 0.262
With Pseudomonas aeruginosa 14 (38.9) 42 (31.8) 0.425
With Klebsiella spp. 6 (16.7) 11 (8.3) 0.207
With Serratia marcescens 3 (8.3) 8 (6.1) 0.704
With Stenotrophomanas maltophilia 6 (16.7) 15 (11.4) 0.400
Multisite infections 18 (50.0) 50 (37.9) 0.189
With urinary tract infection 8 (22.2) 24 (18.2) 0.584
With catheter related infection 2 (5.6) 10 (7.6) 1.000
With skin and soft tissue infection 6 (16.7) 9 (6.8) 0.094 0.214 2.070 (0.657–6.521)
With intra-abdominal infection 3 (8.3) 9 (6.8) 0.721
With invasive fungal infection 3 (8.3) 13 (9.8) 1.000
Microbiology
MDR Acb complex with TG or SB resistancec 7 (19.4) 52 (39.4) 0.026 0.079 0.426 (0.164–1.103)
Airway eradication of MDR Acb complexd 11 (42.3) 62 (49.2) 0.521
Bacteremia during treatment 2 (5.6) 2 (1.5) 0.201
Treatment
Tigecycline-based treatment 21 (58.3) 63 (47.7) 0.259 0.451 1.371 (0.604–3.116)
Duration, days 15.6 (7.9) 15.5 (6.2) 0.519
Combination therapy 25 (69.4) 91 (68.9) 0.954
With cephalosporins 6 (16.7) 22 (16.7) 1.000
With carbapenems 12 (33.3) 53 (40.2) 0.457
With fluoroquinolones 2 (5.6) 14 (10.6) 0.527
With colistin 3 (8.3) 9 (6.8) 0.721
Delayed treatment 9 (25.0) 48 (36.4) 0.202
Abbreviations: MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii, OR odd ratio, CI confidence interval, APACHE acute physiology and
chronic health evaluation, MRSA methicillin resistant Staphylococcus aureus, TG tigecycline, SB sulbactam
aCategorical data are no. (%) of subject, continuous data are expressed as mean (standard deviation)
bAll variables included in the final multivariable model are shown
c The initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group
d26 patients in the deceased group and 126 in the survivors group had available data for evaluation
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Because most patients in sulbactam group had con-
current carbapenem use, the study results in them
might mainly reflect the efficacy of combination of sul-
bactam and carbapenem. In the comparative analyses
of monotherapy, the patients with sulbactam or ampi-
cillin/sulbactam monotherapy had relatively higher
mortality rates than the patients with tigecycline
monotherapy or the overall sulbactam group. The re-
sults implied that combination with carbapenem might
improve clinical outcomes of sulbactam-based treat-
ment. Besides, more than half of the sulbactam group
had sulbactam-resistant MDR Acb complex isolates
during treatment. Combination with carbapenem might
play a role giving a high airway eradication rate. The
Table 3 Multivariate analyses of the predictors for mortality during treatment including combination therapy, carbapenems or
colistin use, and polymicrobial pneumonia
Variables Odds ratio 95 % confidence interval p
Model Aa
With skin and soft tissue infection 2.041 0.644–6.466 0.225
MDR Acb complex with TG or SB resistance 0.418 0.160–1.092 0.075
Bilateral pneumonia 2.663 0.987–7.186 0.053
Tigecycline-based treatment 1.405 0.608–3.245 0.426
Combination therapy 1.133 0.472–2.720 0.779
Model Bb
With skin and soft tissue infection 2.071 0.657–6.523 0.214
MDR Acb complex with TG or SB resistance 0.426 0.163–1.114 0.082
Bilateral pneumonia 2.717 1.007–7.329 0.048
Tigecycline-based treatment 1.373 0.497–3.795 0.541
Combination with carbapenem 1.002 0.346–2.905 0.997
Model Cc
With skin and soft tissue infection 2.002 0.624–6.425 0.243
MDR Acb complex with TG or SB resistance 0.420 0.161–1.090 0.075
Bilateral pneumonia 2.795 1.028–7.600 0.044
Tigecycline-based treatment 1.430 0.608–3.363 0.413
Combination with colistin 0.783 0.178–3.444 0.746
Model D
With skin and soft tissue infection 2.035 0.639–6.485 0.230
MDR Acb complex with TG or SB resistance 0.428 0.165–1.111 0.081
Bilateral pneumonia 2.711 1.013–7.254 0.047
Tigecycline-based treatment 1.362 0.598–3.102 0.462
Polymicrobial pneumonia 1.109 0.426–2.884 0.833
Model E
With skin and soft tissue infection 1.979 0.612–6.405 0.254
MDR Acb complex with TG or SB resistance 0.422 0.160–1.110 0.080
Bilateral pneumonia 2.781 1.014–7.624 0.047
Tigecycline-based treatment 1.422 0.498–4.056 0.510
Polymicrobial pneumonia 1.086 0.413–2.853 0.868
Combination with colistin 0.797 0.179–3.557 0.767
Combination with carbapenem 1.006 0.346–2.921 0.991
Abbreviations: MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii, TG tigecycline, SB sulbactam
aNo significant predictor was revealed when model A included polymicrobial pneumonia
bBilateral pneumonia was the only significant predictor when model B included polymicrobial pneumonia (p = 0.049, adjusted odds ratio, 2.709; 95 % confidential
interval, 1.004–7.305)
cBilateral pneumonia was the only significant predictor when model C included polymicrobial pneumonia (p = 0.045, adjusted odds ratio, 2.783; 95 % confidential
interval, 1.023–7.569)
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Table 4 The comparison and outcome analyses of the patients with monotherapy of tigecycline or sulbactam
Variables TG groupa SB groupa p Deceasedab Survivorsa p
n = 39 n = 13 n = 11 n = 41
Demographic parameters
Age, yr 71.4 (15.0) 68.7 (19.9) 0.899 75.3 (12.0) 69.5 (17.1) 0.439
Male gender 25 (64.1) 10 (76.9) 0.506 8 (72.7) 27 (65.9) 1.000
Concomitant diseases
Hepatic dysfunction 3 (7.7) 0 (0.0) 0.564 1 (9.1) 2 (4.9) 0.518
Renal insufficiency 10 (25.6) 4 (30.8) 0.729 1 (9.1) 13 (31.7) 0.251
Chronic pulmonary disease 11 (28.2) 4 (30.8) 1.000 4 (36.4) 11 (26.8) 0.709
Heart disease 6 (15.4) 1 (7.7) 0.664 2 (18.2) 5 (12.2) 0.630
Diabetes mellitus 9 (23.1) 4 (30.8) 0.714 3 (27.3) 10 (24.4) 1.000
Immune compromise 8 (20.5) 1 (7.7) 0.420 2 (18.2) 7 (17.1) 1.000
Malignancy 8 (20.5) 3 (23.1) 1.000 4 (36.4) 7 (17.1) 0.216
Surgery 9 (23.1) 1 (7.7) 0.419 2 (18.2) 8 (19.5) 1.000
Clinical conditions
APACHE II Score 17.0 (6.1) 18.2 (6.0) 0.557 17.1 (6.8) 17.3 (5.9) 0.904
Ventilator use 21 (53.8) 11 (84.6) 0.048 6 (54.5) 26 (63.4) 0.730
Bilateral pneumonia 18 (46.2) 12 (92.3) 0.004 8 (72.7) 22 (53.7) 0.319
Polymicrobial pneumonia 31 (79.5) 9 (69.2) 0.466 9 (81.8) 31 (75.6) 1.000
With MRSA 20 (51.3) 6 (46.2) 0.749 5 (45.5) 21 (51.2) 0.734
With Pseudomonas aeruginosa 14 (35.9) 3 (23.1) 0.506 5 (45.5) 12 (29.3) 0.470
With Klebsiella spp. 7 (17.9) 1 (7.7) 0.662 1 (9.1) 7 (17.1) 1.000
With Serratia marcescens 5 (12.8) 1 (7.7) 1.000 1 (9.1) 5 (12.2) 1.000
With Stenotrophomanas maltophilia 3 (7.7) 3 (23.1) 0.157 1 (9.1) 5 (12.2) 1.000
Multisite infections 14 (35.9) 5 (38.5) 1.000 4 (36.4) 15 (36.6) 1.000
With urinary tract infection 7 (17.9) 3 (23.1) 0.697 2 (18.2) 8 (19.5) 1.000
With catheter related infection 0 (0.0) 2 (15.4) 0.059 1 (9.1) 1 (2.4) 0.382
With skin and soft tissue infection 3 (7.7) 1 (7.7) 1.000 1 (9.1) 3 (7.3) 1.000
With intra-abdominal infection 4 (10.3) 0 (0.0) 0.561 0 (0.0) 4 (9.8) 0.567
With invasive fungal infection 6 (15.4) 0 (0.0) 0.317 1 (9.1) 5 (12.2) 1.000
Microbiology
MDR Acb complex with TG or SB resistancec 6 (15.4) 4 (30.8) 0.244 1 (9.1) 9 (22.0) 0.668
Airway eradication of MDR Acb complexd 12 (34.3) 8 (88.9) 0.006 4 (57.1) 16 (43.2) 0.684
Bacteremia during treatment 2 (5.1) 0 (0.0) 1.000 1 (9.1) 1 (2.4) 0.382
Treatment
Tigecycline-based treatment 7 (63.6) 32 (78.0) 0.435
Duration, days 13.8 (5.1) 12.7 (5.6) 0.293 11.9 (3.0) 14.0 (5.6) 0.398
Delayed treatment 20 (51.3) 5 (38.5) 0.423 5 (45.5) 20 (48.8) 0.845
Outcomes
Clinical resolution of pneumonia 26 (66.7) 8 (61.5) 0.747
Mortality during treatment 7 (17.9) 4 (30.8) 0.435
30-day mortality 10 (25.6) 7 (53.8) 0.089
Abbreviations: TG tigecycline, SB sulbactam, APACHE acute physiology and chronic health evaluation, MRSA methicillin resistant Staphylococcus aureus, MDR Acb
multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii
aCategorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)
bMortality during treatment
cThe initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group
d35 patients in TG group and 9 in SB group; 7 patients in the deceased group and 37 in the survivors group had available data for evaluation
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patients with sulbactam monotherapy also had a high
airway eradication rate, but most of them did not have
sulbactam-resistant MDR Acb complex.
Synergistic effect against MDRAB with the combin-
ation of sulbactam and carbapenem had been reported
[4, 25]. However, the synergistic effect was associated
with the MICs of carbapenem and sulbactam. If the
MICs exceeded achievable serum levels, the potential of
sulbactam/carbapenem combination as treatment regi-
men for MDRAB infections might be limited [4]. In our
study, full or intermediate sulbactam resistance was de-
tected in 84.5 % of tigecycline-treated patients, therefore,
physicians tended to use tigecycline for these patients
with sulbactam-resistant MDB Acb complex. For these
cases, the clinical outcomes of sulbactam group might
not be achieved if they received sulbactam/carbapenem
combination therapy.
There are some other limitations in this study. First,
our respiratory specimens were clinical specimens from
clinical practice, and they might not be obtained from
deep sites in the lungs. Growths of etiologic pathogens
were assessed semi-quantitatively if the specimens were
qualified for culture. We cannot absolutely distinguish
airway MDR Acb complex infections from colonization.
However, our definition for pneumonia was practical,
and our conclusion based on clinically relevant data
and management could provide important information
for clinical practice. Second, polymicrobial pneumonia
and concomitant infections were common, and the
clinical impact of other etiologic pathogens or extrapul-
monary infections was not evaluated comprehensively.
Third, we studied MDR Acb complex rather than
MDRAB. Although prior studies reported that about
90 % of Acb complex with multidrug or carbapenem
resistance was the genomic specie of A.baumannii,
comparison with studies on A. baumannii isolates are
not straightforward [26].
Conclusions
Tigecycline-based treatment had a similar clinical outcome
to sulbactam or ampicillin/sulbactam-based treatment for
pneumonia involving MDR Acb commplex, but tigecycline
group had a lower microbiological eradiation rate. More
comparison studies are essential to establish the optimal
regimens for pneumonia involving MDR Acb complex.
Abbreviations
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